Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with LenvatinibHaruki Uojima, Wasaburo Koizumi, Makoto Chuma et al.|Liver Cancer|2019Cited by 91
<p>Safety and Efficacy of Lenvatinib Treatment in Child–Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis</p>Katsuaki Ogushi, Shin Maeda, Takahide Nakazawa et al.|Clinical and Experimental Gastroenterology|2020Cited by 55
Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular CarcinomaMakoto Chuma, Shin Maeda, Haruki Uojima et al.|Cancers|2020Cited by 54
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysisMakoto Chuma, Shin Maeda, Haruki Uojima et al.|Hepatology Research|2021Cited by 50
Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus BevacizumabTaito Fukushima, Shin Maeda, Manabu Morimoto et al.|The Oncologist|2023Cited by 42